Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samuel Zachary Goldhaber, M.D.

Co-Author

This page shows the publications co-authored by Samuel Goldhaber and Cheng-Liang Chi.
Connection Strength

4.331
  1. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
    View in: PubMed
    Score: 0.802
  2. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.
    View in: PubMed
    Score: 0.783
  3. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Am J Med. 2018 08; 131(8):972.e1-972.e7.
    View in: PubMed
    Score: 0.756
  4. Machine learning to predict venous thrombosis in acutely ill medical patients. Res Pract Thromb Haemost. 2020 Feb; 4(2):230-237.
    View in: PubMed
    Score: 0.214
  5. Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. TH Open. 2019 Apr; 3(2):e103-e108.
    View in: PubMed
    Score: 0.203
  6. Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation. 2019 02 26; 139(9):1234-1236.
    View in: PubMed
    Score: 0.201
  7. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec; 118(12):2046-2052.
    View in: PubMed
    Score: 0.197
  8. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.
    View in: PubMed
    Score: 0.185
  9. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.
    View in: PubMed
    Score: 0.184
  10. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017 Nov; 44(4):457-465.
    View in: PubMed
    Score: 0.183
  11. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 10; 15(10):1913-1922.
    View in: PubMed
    Score: 0.181
  12. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017 Jun; 1(1):e56-e65.
    View in: PubMed
    Score: 0.179
  13. Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open. 2018 Jan; 2(1):e16-e24.
    View in: PubMed
    Score: 0.046
  14. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018 04; 198:84-90.
    View in: PubMed
    Score: 0.046
  15. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
    View in: PubMed
    Score: 0.045
  16. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. Am Heart J. 2017 07; 189:1-8.
    View in: PubMed
    Score: 0.044
  17. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
    View in: PubMed
    Score: 0.043
  18. D-Dimer elevation and adverse outcomes. J Thromb Thrombolysis. 2015 Jan; 39(1):55-9.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.